Cargando…

Palmitic Acid-Conjugated Radiopharmaceutical for Integrin α(v)β(3)-Targeted Radionuclide Therapy

Peptide receptor radionuclide therapy (PRRT) is an emerging approach for patients with unresectable or metastatic tumors. Our previously optimized RGD peptide (3PRGD(2)) has excellent targeting specificity for a variety of integrin α(v)β(3)/α(v)β(5)-positive tumors and has been labeled with the ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Guangjie, Gao, Hannan, Luo, Chuangwei, Zhao, Xiaoyu, Luo, Qi, Shi, Jiyun, Wang, Fan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321335/ https://www.ncbi.nlm.nih.gov/pubmed/35890224 http://dx.doi.org/10.3390/pharmaceutics14071327

Ejemplares similares

Therapeutic Radiopharmaceuticals Targeting Integrin αvβ6
por: Färber, Stefanie Felicitas, et al.
Publicado: (2018)

A Dual pH-Responsive DOX-Encapsulated Liposome Combined with Glucose Administration Enhanced Therapeutic Efficacy of Chemotherapy for Cancer
por: Zhai, Luoping, et al.
Publicado: (2021)

Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Airaksinen, A, et al.
Publicado: (2016)

Radiopharmaceuticals and other compounds labelled with short-lived radionuclides
por: Welch, Michael J
Publicado: (2013)

Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Domnanich, Katharina, et al.
Publicado: (2014)

Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Dorrer, H, et al.
Publicado: (2011)

Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals()
por: Cai, Zhengxin, et al.
Publicado: (2013)

(188)Re(V) Nitrido Radiopharmaceuticals for Radionuclide Therapy
por: Boschi, Alessandra, et al.
Publicado: (2017)

IS528 Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Koester, Ulli, et al.
Publicado: (2018)

IS528 Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Köster, Ulli
Publicado: (2017)

Radiopharmaceutical Treatments for Cancer Therapy, Radionuclides Characteristics, Applications, and Challenges
por: Salih, Suliman, et al.
Publicado: (2022)

Palmitate up-regulates laminin expression via ROS/integrin αvβ3 pathway in HLSECs
por: Zhang, Qi, et al.
Publicado: (2019)

It’s Time to Shift the Paradigm: Translation and Clinical Application of Non-αvβ3 Integrin Targeting Radiopharmaceuticals
por: Kossatz, Susanne, et al.
Publicado: (2021)

Development and optimization of targeted radionuclide tumor therapy using folate based radiopharmaceuticals
por: Reber, Josefine Astrid
Publicado: (2015)

Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
por: Hennrich, Ute, et al.
Publicado: (2019)

The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker
por: Holik, Holis Abdul, et al.
Publicado: (2022)

Integrin-α9β1 as a Novel Therapeutic Target for Refractory Diseases: Recent Progress and Insights
por: Xu, Shihan, et al.
Publicado: (2021)

Heterogeneity of dose distribution in normal tissues in case of radiopharmaceutical therapy with alpha-emitting radionuclides
por: Li, Wei Bo, et al.
Publicado: (2022)

TNF-α stimulates endothelial palmitic acid transcytosis and promotes insulin resistance
por: Li, Wenjing, et al.
Publicado: (2017)

Mechanisms of palmitic acid-conjugated antisense oligonucleotide distribution in mice
por: Chappell, Alfred E, et al.
Publicado: (2020)

Evaluation of Acridine Orange Derivatives as DNA-Targeted Radiopharmaceuticals for Auger Therapy: Influence of the Radionuclide and Distance to DNA
por: Pereira, Edgar, et al.
Publicado: (2017)

Autophagy Induced by Palmitic Acid Regulates Neutrophil Adhesion Through the Granule-Dependent Degradation of αMβ2 Integrin in Dairy Cows With Fatty Liver
por: Peng, Zhicheng, et al.
Publicado: (2021)

PET Radiopharmaceuticals for Imaging Integrin Expression: Tracers in Clinical Studies and Recent Developments
por: Haubner, Roland, et al.
Publicado: (2014)

[(123)I]CC1: A PARP-Targeting, Auger Electron–Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer
por: Chan, Chung Ying, et al.
Publicado: (2023)

An efficient method for the site-specific (99m)Tc labeling of nanobody
por: Luo, Qi, et al.
Publicado: (2021)

In vivo evaluation of integrin αvβ6-targeting peptide in NSCLC and brain metastasis
por: Fan, Di, et al.
Publicado: (2023)

Integrin α(v)β(3)-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy
por: Chen, Haojun, et al.
Publicado: (2019)

Palmitic acid conjugation enhances potency of tricyclo-DNA splice switching oligonucleotides
por: Relizani, Karima, et al.
Publicado: (2021)

CeO(2)-Azacrown Conjugate as a Nanoplatform for Combined Radiopharmaceuticals
por: Khabirova, Sofia, et al.
Publicado: (2022)

Atezolizumab-Conjugated Poly(lactic acid)/Poly(vinyl alcohol) Nanoparticles as Pharmaceutical Part Candidates for Radiopharmaceuticals
por: Ekinci, Meliha, et al.
Publicado: (2022)

Multivalency Increases the Binding Strength of RGD Peptidomimetic‐Paclitaxel Conjugates to Integrin α(V)β(3)
por: Raposo Moreira Dias, André, et al.
Publicado: (2017)

Antitumor activity of integrin α(V)β(3) antibody conjugated-cationic microbubbles in liver cancer
por: Li, Jiale, et al.
Publicado: (2019)

An innovative gamma-ray spectrometry system using a compact and portable CZT detector for radionuclidic purity tests of PET radiopharmaceuticals
por: Vichi, Sara, et al.
Publicado: (2016)

Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy
por: Xu, Mengxin, et al.
Publicado: (2022)

FITC-Conjugated Cyclic RGD Peptides as Fluorescent Probes for Staining Integrin α(v)β(3)/α(v)β(5) in Tumor Tissues
por: Zheng, Yumin, et al.
Publicado: (2014)

Anti-α(4)β(7) monoclonal antibody–conjugated nanoparticles block integrin α(4)β(7) on intravaginal T cells in rhesus macaques
por: Yang, Sidi, et al.
Publicado: (2020)

Radiopharmaceuticals for therapy
por: Knapp, F F (Russ), et al.
Publicado: (2016)

PET Radiopharmaceuticals
por: Shahhosseini, Soraya
Publicado: (2011)

Pharmacovigilance in radiopharmaceuticals
por: Kumar, Rishi, et al.
Publicado: (2016)

Targeting integrin α5β1 in urological tumors: opportunities and challenges
por: Zhou, Xuming, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1ssjkla5g0e0j4rdivkoudk693